Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-β

Cancer Research

Volumn 59, Issue 4, 1999, Pages 872-879

  Dong, Zhongyun ^a   Greene, Graham ^a   Pettaway, Curtis ^a   Dinney, Colin P N ^a   Eue, Ines ^a   Lu, Weixin ^a   Bucana, Corazon D ^a   Balbay, Mevlana D ^a   Bielenberg, Diane ^a   Fidler, Isaiah J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON;

ANGIOGENESIS; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MACROPHAGE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR GROWTH;

ANIMALS; CYTOTOXICITY, IMMUNOLOGIC; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; INTERFERON-BETA; KILLER CELLS, NATURAL; MACROPHAGES; MALE; MICE; MICE, NUDE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; PROSTATIC NEOPLASMS;

EID: 0033557916     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Wingo, P. A., Tong, T., and Bolden, S. Cancer statistics, 1995. CA Cancel J. Clin., 45: 8-30, 1995.
2. Fidler, I. J. Critical factors in the biology of human cancer metastasis. Twenty-eighth Clowes Memorial Award Lecture. Cancer Res., 50, 6130-6138, 1990.
3. Folkman, J. Clinical applications of research on angiogenesis. N. Engl. J. Med., 333: 1757-1763, 1995.
4. Fidler, I. J., and Ellis, L. M. The implications of angiogenesis to the biology and therapy of cancer metastasis. Cell, 79: 185-188, 1994.
5. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86: 353-364, 1996.
6. Singh, R. K., Bucana, C. D., Gutman, M., Fan, D., Wilson, M. R., and Fidler, I. J. Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am. J. Pathol., 145: 365-374, 1994.
7. Dvorak, H. F., Brown, L. F., Detmar, M., and Dvorak, A. M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol., 146: 1029-1039, 1995.
8. Singh, R. K., Gutman, M., Radinsky, R., Bucana, C. D., and Fidler, I. J. Expression of interleukin-8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res., 54: 3242-3246, 1994.
9. Koch, A. E., Friedman, J., Burrows, J. C., Haines, G. K., and Bouch, N. P. Localization of the angiogenesis inhibitor thrombospondin in human synovial tissues. Pathobiology, 61: 1-6, 1993.
10. O'Reilly, M. S., Holmgren, L., Shing, Y., Chen, C., Rosenthal, R. A., Moses, M., Lane, W. S., Cao, Y., Sage, E. H., and Folkman, J. Angiostatin: a novel angiogenesis inhibitor that meditates the suppression of metastases by a Lewis lung carcinoma. Cell, 79: 315-328, 1994.
11. Sim, B. K. O'Reilly, M. S., Liang, H., Fortier, A. H., He, W., Madsen, J. W., Lapcevich, R., and Nacy, C. A. A recombinant human angiostatin protein inhibits experimental primary and metastatic cancer. Cancer Res., 57: 1329-1334, 1997.
12. Dong, Z., Kumar, R., Yang, X., and Fidler, I. J. Macrophage-derived metalloclastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell, 88: 801-810, 1997.
13. Singh, R. K., Gutman, M., Bucana, C. D., Sanchez, R., Llansa, N., and Fidler, I. J. Interferons alpha and beta downregulate the expression of basic fibroblast growth factor in human carcinomas. Proc. Natl. Acad. Sci. USA, 92: 4562-4566, 1995.
14. Baron, S., and Dianzani, F. The interferons: a biological system with therapeutic potential in viral infections. Antiviral Res., 24: 97-110, 1994.
15. Hertzog, P. J., Hwang, S. Y., and Kola, I. Role of interferons in the regulation of cell proliferation, differentiation, and development. Mol. Reprod. Dev., 39: 226-232, 1994.
16. Brzoska, J., and Obert, H-J. Immunomodulating effects of interferons: conclusions for therapy. In: G. Gross, S. Jablonska, H. Pfister, and H. E. Stegner (eds.), Genital Papillomavirus Infections, pp. 379-391. Berlin: Springer-Verlag, 1990.
17. Krown, S. E. Interferons in malignancy: biological products or biological response modifiers? J. Natl. Cancer Inst., 80: 306-309, 1988.
18. Thomas, H., and Balkwill, F. R. Effects of interferons and other cytokines on tumors in animals: a review. Pharmacol. Ther., 52: 307-314, 1991.
19. Bulbul, M. A., Huben, R. P., and Murphy, G. P. Interferon-β treatment of metastatic prostate cancer. J. Surg. Oncol., 33: 231-233, 1986.
20. Schiller, J. H., Storer, B., Bittner, G., Wilson, J. K., and Bordon, E. C Phase II trial of a combination of interferon-β ser and interferon-γ in patients with advanced malignant melanoma. J. Interferon Res., 8: 581-589, 1988.
21. Einhorn, S., and Grander, D. Why do so many cancer patients fail to respond to interferon therapy? J. Interferon Cytokine Res., 16: 275-281, 1996.
22. Ozzello, L., Habif, D. V., and DeRosa, C. M. Antiproliferative effects of natural interferon β alone and in combination with natural interferon γ on human breast carcinomas in nude mice. Breast Cancer Res. Treat., 16: 89-96, 1990.
23. Gutterman, J. U. Cytokine therapeutics: lessons from interferon-α. Proc. Natl. Acad. Sci. USA. 91: 1198-1205, 1994.
24. Wu, J. M., Lin, C. S., Wang, J. N., Luo, C. Y., Yu, C. Y., and Yang, H. B. Pulmonary cavernous hemangiomatosis treated with interferon α-2a. Pediatr. Cardiol., 17: 332-334, 1996.
25. Castello, M. A., Ragni, G., Antimi, A., Todini, A., Patti, G., Lubrano, R., Clerico, A., and Calisti, A. Successful management with interferon α-2a after prednisone therapy failure in an infant with a giant cavernous hemangioma. Med. Pediatr. Oncol., 28: 213-215, 1997.
26. Shepherd, F. A., Beaulieu, R., Gelmon, K., Thuot, C. A., Sawka, C., Read, S., and Singer, J. Prospective randomized trial of two dose levels of interferon α with zidovudine for the treatment of Kaposi's sarcoma associated with human immunodeficiency virus infection: a Canadian HIV clinical trials network study. J. Clin. Oncol., 16: 1736-1742, 1998.
27. Kim, D. H., and Kramer, A. Long-term freedom from disease progression with interferon a therapy in two patients with malignant hemangiopericytoma. J. Natl. Cancer Inst., 88: 764-765, 1996.
28. Dinney, C. P. N., Bielenberg, D. R., Perrotte, P., Reich, R., Eve, B. Y., Bucana, C. D., and Fidler, I. J. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by mice by systemic interferon-α administration. Cancer Res., 58: 808-814, 1998.
29. Vermeulen, P. B., Diriz, L. Y., Martin, M., Lemmens, J., and Van Oosterom, A. T. Serum basic fibroblast growth factor and vascular endothelial growth factor in metastatic renal cell carcinoma treated with interferon α-2b. J. Natl. Cancer Inst., 89: 1316-1317, 1997.
30. Oliveira, I. C., Sciavolino, P. J., and Lee, T. H. Downregulation of interleukin 8 gene expression in human fibroblasts: unique mechanism of transcriptional inhibition by interferon. Proc. Natl. Acad. Sci. USA, 89: 9049-9053, 1992.
31. Van Damme, J., and Opdenakker, G. Interaction of interferons with skin reactive cytokines: from interleukin-1 to interleukin-8. J. Invest. Dermatol., 95: 90S-93S, 1990.
32. Gohji, K., Fidler, I. J., Tsan, R., Radinsky, R., von Eschenbach, A. C., Tsuruo, T., and Nakajima, M. Human recombinant interferons-β and γ decrease gelatinase production and invasion by human KG-2 renal carcinoma cells. Int. J. Cancer, 58: 380-384, 1994.
33. Fabra, A., Nakajima, M., Bucana, C. D., and Fidler, I. J. Modulation of the invasive phenotype of human colon carcinoma cells by organ-specific fibroblasts of nude mice. Differentiation, 52: 101-110, 1992.
34. Salmon, P., Le Cotonnec, J. Y., Galazka, A., Abdul-Ahad, A., and Darragh, A. Pharmacokinetics and pharmacodynamics of recombinant human interferon-β in healthy male volunteers. J. Interferon Cytokine Res., 16: 759-764, 1996.
35. Kaido, T., Bandu, M. T., Ferrrantini, M., Belardelli, F., and Gresser, I. IFN-α gene transfection completely abolishes the tumorigenicity of murine B16 melanoma cells in allogeneic DBA/2 mice and decreases their tumorigenicity in syngeneic C57BL/6 mice. Int. J. Cancer, 60: 221-227, 1995.
36. Sarkar, S., Flores, I., De Rosa, C. Ozzello, L. Ron, Y., and Pestak, S. Injection of irradiated B16 melanoma genetically modified to secrete IFN-α causes regression of an established tumor. Int. J. Oncol., 7: 17-24, 1995.
37. Fleischmann, C. M., Stanton, G. J., and Fleischmann, W. R., Jr. Enhanced in vivo sensitivity to interferon with in vitro resistant B16 tumor cells in mice. Cancer Immunol. Immunother., 39: 148-154, 1994.
38. Sica, G., Fabbroni, L., Gastagnetta, L., Cacciatore, M., and Pavone-Macaluso, M. Antiproliferative effect of interferons on human prostate carcinoma cell lines. Urol. Res., 17: 111-115, 1989.
39. Kozlowski, J. M., Fidler, I. J., Campbell, D., Xu, Z. L., Kaighn, M. E., and Hart, I. R. Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res., 44: 3522-3529, 1984.
40. Stephenson, R. A., Dinney, C. P. N., Gohji, K., Ordonez, N. G., Killion, J. J., and Fidler, I. J. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J. Natl. Cancer Inst., 84: 951-957, 1992.
41. Miller, A. D., and Buttimore, C. Redesign of retrovirus packaging cell lines to avoid recombination leading helper virus production. Mol. Cell. Biol., 6: 2895-2902, 1986.
42. Talmadge, J. K., Meyers, K. M., Prieur, D. J., and Starkey, J. R. Role of natural killer cells in tumor growth and metastasis: C57BL/6 normal and beige mice. J. Natl. Cancer Inst., 65: 929-935, 1980.
43. Dong, Z., Qi, X., and Fidler, I. J. Tyrosine phosphorylation of mitogen-activated protein kinases is necessary for activation of murine macrophages by natural and synthetic bacterial products. J. Exp. Med., 177: 1071-1077, 1993.
44. Gavrieli, Y., Shermen, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell. Biol., 119: 493-501, 1992.
45. Fujihara, M., Ito, N., Pace, J. L., Watanabe, Y., Russell, S. W., and Suzuki, T. Role of endogenous interferon-β in lipopolysaccharide-triggered activation of the inducible nitric-oxide synthase gene in a mouse macrophage cell line. J774. J. Biol. Chem., 269: 12773-12778, 1994.
46. Dong, Z., Juang, P., S. H., Kumar, R., Eue, I., Xie, K., Bielenberg, D., Yang, X., and Fidler, I. J. Expression of interferon-β in UV2237m mouse fibrosarcoma cells suppressed their tumorigenicity and metastasis in syngencic mice. Cancer Immunol. Immunother., 46: 137-146, 1998.
47. Fujimiya, Y., Wagner, R. J., Groveman, S., Sielaff, K., Kohsaka, T., and Nakayama, M. In vivo priming effects of interferon-β ser on NK activity of peripheral blood mononuclear cells in cancer patients. Ther. Immunol., 2: 15-22, 1995.
48. Senik, A., Gresser, I., Maury, C., Gidlund, M., Orn, A., and Wigzell, H. Enhancement by interferon of natural killer cell activity in mice. Cell Immunol., 44: 186-200, 1979.
49. Kasai, M., Yoneda, T., Habu, S., Maruyama, Y., Okumura, K., and Tokunaga, T. In vivo effects of anti-asialo GM1 antibody on natural killer activity. Nature (Lond.), 291: 334-337, 1981.
50. Wilson, G. D. Camplejohn, R. S., Martindale, C. A., Brock, A., Lane, D. P., and Barnes, D. M. Flow cytometric characterization of proliferating cell nuclear antigen using the monoclonal antibody PC10. Eur J. Cancer, 12: 2010-2017, 1992.
51. Hughes, D. A., Fraser, I. P., and Gordon, S. Murine macrophage scavenger receptor: in vivo expression and function as receptor for macrophage adhesion in lymphoid and non-lymphoid organs. Eur. J. Immunol., 25: 466-473, 1995.
52. Riches, D. W., and Underwood, G. A. Expression of interferon-β during the triggering phase of macrophage cytocidal activation: evidence for an autocrine/paracrine role in the regulation of this state. J. Biol. Chem., 266: 24785-24792, 1991.
53. Steuhr, D. J., and Nathan, C. F. Nitric oxide. A macrophage produce responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med., 169: 1543-1555, 1989.
54. Xie, K., Dong, Z., and Fidler, I. J. Activation of nitric oxide synthase gene for inhibition of cancer metastasis. J. Leukocyte Biol., 59: 797-803, 1996.
55. Xie, K., Bielenberg, D., Huang, S., Xu, L., Salas, T., Juang, S., Dong, Z., and Fidler, I. J. Abrogation of tumorigenicity and metastasis of murine and human tumor cells by transfection with murine interferon β gene: possible role of nitric oxide. Clin. Cancer Res., 3: 2283-2294, 1997.
56. Targan, S., and Dorey, F. Interferon activation of "pre-spontaneous killer" (Pre-Sk) cells and alteration in kinetics of lysis of both "pre-SK" and active SK cells. J. Immunol., 124: 2157-2167, 1980.
57. Liu, C. C., Perussia, B., Cohen, Z. A., and Young, J. D-E. Identification and characterization of a pore-forming protein of human peripheral blood natural killer cells. J. Exp. Med., 164: 2061-2071, 1986.
58. Folkman, J. The role of angiogenesis in tumor growth. Semin. Cancer Biol., 3: 65-71, 1992.
59. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
60. Folkman, J., Merler, E., Abernathy, C., and Williams, G. Isolation of a tumor factor responsible for angiogenesis. J. Exp. Med., 133: 275-288, 1971.
61. Dvorak, H. F. Tumor wounds that do not heal: similarities between tumor stroma generation and wound healing. N. Engl. J. Med., 315: 1650-1659, 1986.
62. Klagsbrun, M., and D'Amore, P. A. Regulators of angiogenesis. Annu. Rev. Physiol., 53: 217-239, 1991.
63. Polverini, P. I., and Leiboviach, S. J. Induction of neovascularization in vivo and endothelial proliferation in vitro by tumor-associated macrophages. Lab. Invest., 51: 635-642, 1984.
64. Folkman, J., and Klagsbrun, M. Angiogenic factors. Science (Washington DC), 235: 442-447, 1987.
65. Sunderkotter, C., Goebeler, M., Schulze-Osthoff, K., Bhardwaj, R., and Sorg, C. Macrophage-derived angiogenesis factors. Pharmacol. Ther., 51: 195-216, 1991.
66. Singh, R. K., Gutman, M., Llansa, N., and Fidler, I. J. Interferon-β prevents the upregulation of interleukin-8 expression in human melanoma cells. J. Interferon Cytokine Res., 16: 577-584, 1996.